83 related articles for article (PubMed ID: 11306743)
1. Clinical impacts of tumor cell contamination of hematopoietic stem cell products in metastatic breast cancer patients undergoing autologous peripheral blood stem cell transplantation: multicenter trial.
Ahn MJ; Noh YH; Lee YS; Lee YY; Choi IY; Kim IS; Joh EK; Shin DB; Kim SY; Cho KS; Kim HC; Kim HS; Suh CW; Kim SH; Lee JA; Park YS
J Korean Med Sci; 2001 Apr; 16(2):175-82. PubMed ID: 11306743
[TBL] [Abstract][Full Text] [Related]
2. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
[TBL] [Abstract][Full Text] [Related]
3. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.
Quintela-Fandino M; López JM; Hitt R; Gamarra S; Jimeno A; Ayala R; Hornedo J; Guzman C; Gilsanz F; Cortés-Funes H
J Clin Oncol; 2006 Aug; 24(22):3611-8. PubMed ID: 16877728
[TBL] [Abstract][Full Text] [Related]
5. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH
N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
[TBL] [Abstract][Full Text] [Related]
8. Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy.
Viret F; Chabannon C; Sainty D; Genre D; Gonçalves A; Arnoulet C; Gravis G; Bertucci F; Houvenaeghel G; Jacquemier J; Bardou VJ; Ladaique P; Braud AC; Maraninchi D; Viens P
Bone Marrow Transplant; 2003 Dec; 32(11):1059-64. PubMed ID: 14625576
[TBL] [Abstract][Full Text] [Related]
9. Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation.
Reed E; Kessinger A; Murphy B; Tarantolo S; Traystman M; Sharp JG
Bone Marrow Transplant; 2003 Apr; 31(7):571-4. PubMed ID: 12692623
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
11. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
12. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer.
Jotsuka T; Okumura Y; Nakano S; Nitta H; Sato T; Miyachi M; Suzumura K; Yamashita J
Surgery; 2004 Apr; 135(4):419-26. PubMed ID: 15041966
[TBL] [Abstract][Full Text] [Related]
13. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
Viens P; Palangié T; Janvier M; Fabbro M; Roché H; Delozier T; Labat JP; Linassier C; Audhuy B; Feuilhade F; Costa B; Delva R; Cure H; Rousseau F; Guillot A; Mousseau M; Ferrero JM; Bardou VJ; Jacquemier J; Pouillart P
Br J Cancer; 1999 Oct; 81(3):449-56. PubMed ID: 10507769
[TBL] [Abstract][Full Text] [Related]
14. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
[TBL] [Abstract][Full Text] [Related]
16. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
18. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy.
Vredenburgh JJ; Madan B; Coniglio D; Ross M; Broadwater G; Niedzwiecki D; Edwards J; Marks L; Vandemark R; McDonald C; Affronti ML; Peters WP
Bone Marrow Transplant; 2006 Jun; 37(11):1009-15. PubMed ID: 16633363
[TBL] [Abstract][Full Text] [Related]
20. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment.
Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G
Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
